Cord-Haplo Identical Non-in-vitro T-cell-depletion Allogeneic Hematopoietic Stem Cell Transplantation Reduces Relapse for Refractory Acute Leukemia
Refractory acute leukemia (AL) has a dismal prognosis and represents a tremendous therapeutic challenge. Conventional allogeneic hematopoietic stem cell transplantation (allo-HSCT) only yields long-term survival rates in 7 –24% of patients with refractory acute lymphocytic leukemia and 10–40% of those with late-stage acute myeloid leukemia (AML) [1-6]. Although several recent studies of allo-HSCT using 2 grafts (i.e., double-umbilical cord blood [UCB] transplantation [dUCBT]) and haplo-cord HSCT have shown an enha nced graft-versus-leukemia (GVL) effect along with a graft-versus-graft (GVG) response [4, 7-17], this finding is still controversial [9, 14, 18, 19].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Jingbo Wang, Zheng Wang, Wei Wei, Weijie Zhang, Tao Zhang, Haoyu Cheng, Xinhong Fei, Yuming Yin, Jiangying Gu, Lei Yuan Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants